RSC-133 Indoleacrylic Acid for Pluripotent Stem Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing human pluripotent stem cells face challenges such as low efficiency, safety concerns due to viral vectors, ethical issues with embryonic stem cells, and immune rejection, along with difficulties in maintaining undifferentiated states and large-scale production.
Innovation Solution
A novel low-molecular-weight compound, RSC-133, is introduced, which is used in a cell culture medium to enhance reprogramming efficiency and maintain pluripotency, replacing the need for viral vectors and improving culture conditions by promoting the reprogramming of differentiated cells into pluripotent stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used for reprogramming, then reprogramming efficiency is improved, but safety concerns increase due to potential genomic integration and tumorigenicity
Solution Approach 1:
The patent extracts and eliminates the viral vector component from the reprogramming system, replacing it with small molecule compounds (RSC-133) and non-viral methods. This removes the harmful genomic integration risk while maintaining reprogramming functionality through alternative molecular mechanisms.
Solution Approach 2:
The patent employs small molecule compounds that act transiently during reprogramming without permanent genomic integration. These short-acting molecules achieve the desired epigenetic modifications and gene expression changes without the long-term safety risks of viral integration, allowing the system to be 'disposable' rather than permanently altering the genome.
2Productivity
If embryonic stem cells are used, then pluripotent stem cell production is achieved, but ethical issues and immune rejection problems arise
Solution Approach 1:
The patent uses small molecule compounds (RSC-133) as intermediaries to mediate the reprogramming process. These molecules facilitate the transition from differentiated cells to pluripotent stem cells without requiring embryonic destruction, thereby avoiding ethical issues while preventing immune rejection through patient-specific cell generation.
Solution Approach 2:
The patent replaces the mechanical/biological process of embryo extraction and manipulation with a chemical reprogramming approach using small molecules. This substitution eliminates the need for embryo destruction (resolving ethical issues) and enables autologous cell therapy (resolving immune rejection) by reprogramming the patient's own cells.
3Reliability
If chemically defined media without animal feeder cells is used, then safety is improved by eliminating infectious agents, but manufacturing complexity increases
Solution Approach 1:
The patent modifies the chemical parameters of the culture medium by adding specific small molecule compounds (RSC-133) to chemically defined media. This parameter change enables the media to support pluripotent stem cell maintenance and reprogramming without requiring animal feeder cells, thereby maintaining safety while simplifying the manufacturing process through defined chemistry.
4Productivity
If large-scale production of undifferentiated stem cells is pursued, then productivity is improved, but maintaining undifferentiated state becomes more difficult
Solution Approach 1:
The patent employs continuous treatment with small molecule compounds (RSC-133) during culture to maintain the undifferentiated state. This continuous molecular action prevents differentiation signals from taking effect, allowing large-scale production while preserving the pluripotent undifferentiated state through sustained chemical protection.
Solution Approach 2:
The small molecule compounds act as intermediaries that block differentiation pathways during large-scale culture. These molecules mediate between the culture conditions and the stem cells, preventing unwanted differentiation while allowing scalable production without compromising cell state stability.
Data Source
AI summary
Provided herein are novel indoleacrylic acid-based compounds, and pharmaceutically acceptable salts thereof, useful for the production, maintenance and proliferation of pluripotent stem cells. Also provided are cell culture compositions comprising these compounds, and methods of using these compounds in the production and maintenance of pluripotent stem cells.